血红素病市场－全球产业规模、份额、趋势、机会及预测，依类型（地中海型贫血、镰状细胞疾病、其他血红素变异体）、诊断、治疗、地区和竞争格局划分，2020-2030年预测

2024年全球血红素病市场规模为84.4亿美元，预计2030年将以12.7%的复合年增长率成长至172.9亿美元。血红蛋白疾病是一组遗传性血液疾病，其特征是血红蛋白分子的结构或生成异常，而血红蛋白分子对于红血球内的氧气运输至关重要。全球血红蛋白疾病市场成长的主要驱动因素是这些遗传性疾病在全球的盛行率不断上升，以及诊断技术和治疗方法的显着进步。

主要市场驱动因素

主要市场挑战

主要市场趋势

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：顾客之声

第五章：全球血红素疾病市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依类型（地中海型贫血、镰状细胞疾病、其他血红素（Hb）变异体）
  • 依诊断（地中海型贫血{血液检查、基因检测、产前基因检测、胚胎植入前遗传学诊断、电泳、其他}、镰状细胞疾病{血液检查、基因检测、产前基因检测、电泳、其他}、其他{血液检查、基因检测、产前基因检测、电泳、其他}）
  • 依治疗方法分类（地中海型贫血{输血、铁螯合疗法、骨髓移植、其他}、镰状细胞疾病{输血、羟基脲、骨髓移植、其他}、其他{输血、羟基脲、铁螯合疗法、骨髓移植、其他}）
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美血红素疾病市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲血红素病市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区血红素疾病市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲血红素疾病市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美洲血红素疾病市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购（如有）
• 产品发布（如有）
• 最新进展

第十三章：全球血红素疾病市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• Sangamo Therapeutics, Inc.
• Pfizer, Inc. (Global Blood Therapeutics, Inc.)
• bluebird bio, Inc.
• Emmaus Medical, Inc.
• Novartis AG
• Prolong Pharmaceuticals, LLC
• Sanofi SA (Bioverativ Inc.)
• Gamida Cell Ltd.
• Celgene Corporation
• Abbott Laboratories, Inc.

第十六章：策略建议

第17章调查会社について・免责事项

The Global Hemoglobinopathies Market , valued at USD 8.44 Billion in 2024, is projected to experience a CAGR of 12.7% to reach USD 17.29 Billion by 2030. Hemoglobinopathies represent a group of inherited blood disorders characterized by abnormalities in the structure or production of the hemoglobin molecule, crucial for oxygen transport within red blood cells. The global market for these conditions is primarily driven by the increasing worldwide prevalence of these genetic disorders and significant advancements in diagnostic technologies and therapeutic interventions.

Key Market Drivers

The global hemoglobinopathies market is significantly influenced by the increasing worldwide prevalence of these genetic disorders and the continuous emergence of novel and gene-based therapies. The rising prevalence contributes directly to a larger patient pool requiring diagnosis, treatment, and ongoing care, thereby expanding the overall market demand. According to The Lancet Haematology, in June 2023, the number of people living with sickle cell disease globally increased by 41.4% from 2000 to 7.74 million in 2021, highlighting a substantial and growing patient population. This demographic shift necessitates enhanced healthcare resources and drives investments in therapeutic solutions.

Key Market Challenges

The substantial cost associated with novel, advanced therapies, particularly gene therapies and bone marrow transplantation, represents a significant impediment to the global hemoglobinopathies market's expansion. These treatments, while offering the potential for transformative outcomes, are often accompanied by prohibitively high price tags. For instance, according to the Sickle Cell Disease Association of America, in December 2023, the list price for Casgevy, a gene therapy for sickle cell disease, was estimated at $2.2 million, while Lyfgenia, another gene therapy for the same condition, was estimated at $3.1 million.

Key Market Trends

Artificial intelligence is a significant trend, enhancing diagnostic precision and efficiency for hemoglobinopathies by streamlining complex data analysis. This technology leverages genetic information and medical records for quicker and more accurate disorder identification. While its potential is substantial, challenges remain; according to the National Institutes of Health, in August 2024, the best-performing AI models achieved only 21 percent accurate diagnoses from patient-written genetic condition descriptions, emphasizing areas for refinement. Despite these, AI proves impactful in personalized monitoring.

Key Market Players

• Sangamo Therapeutics, Inc.
• Pfizer, Inc. (Global Blood Therapeutics, Inc.)
• bluebird bio, Inc.
• Emmaus Medical, Inc.
• Novartis AG
• Prolong Pharmaceuticals, LLC
• Sanofi S.A. (Bioverativ Inc.)
• Gamida Cell Ltd.
• Celgene Corporation
• Abbott Laboratories, Inc.

Report Scope:

In this report, the Global Hemoglobinopathies Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Hemoglobinopathies Market , By Type:

• Thalassemia
• Sickle Cell Disease
• Other Hemoglobin (Hb) Variants

Hemoglobinopathies Market , By Diagnosis:

• Thalassemia {Blood Test, Genetic Test, Prenatal Genetic Test, Pre-implantation Genetic Diagnosis, Electrophoresis, Others}
• Sickle Cell Disease {Blood Test, Genetic Test, Prenatal Genetic Test, Electrophoresis, Others}
• Other {Blood Test, Genetic Test, Prenatal Genetic Test, Electrophoresis, Others}

Hemoglobinopathies Market , By Therapy:

• Thalassemia {Blood Transfusion, Iron Chelation Therapy, Bone Marrow Transplant, Others}
• Sickle Cell Disease {Blood Transfusion, Hydroxyurea, Bone Marrow Transplant, Others}
• Other {Blood Transfusion, Hydroxyurea, Iron Chelation Therapy, Bone Marrow Transplant, Others}

Hemoglobinopathies Market , By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Hemoglobinopathies Market .

Available Customizations:

Global Hemoglobinopathies Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Hemoglobinopathies Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Thalassemia, Sickle Cell Disease, Other Hemoglobin (Hb) Variants)
  • 5.2.2. By Diagnosis (Thalassemia {Blood Test, Genetic Test, Prenatal Genetic Test, Pre-implantation Genetic Diagnosis, Electrophoresis, Others}, Sickle Cell Disease {Blood Test, Genetic Test, Prenatal Genetic Test, Electrophoresis, Others}, Other {Blood Test, Genetic Test, Prenatal Genetic Test, Electrophoresis, Others})
  • 5.2.3. By Therapy (Thalassemia {Blood Transfusion, Iron Chelation Therapy, Bone Marrow Transplant, Others}, Sickle Cell Disease {Blood Transfusion, Hydroxyurea, Bone Marrow Transplant, Others}, Other {Blood Transfusion, Hydroxyurea, Iron Chelation Therapy, Bone Marrow Transplant, Others})
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Hemoglobinopathies Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Diagnosis
  • 6.2.3. By Therapy
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Hemoglobinopathies Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Diagnosis
      • 6.3.1.2.3. By Therapy
  • 6.3.2. Canada Hemoglobinopathies Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Diagnosis
      • 6.3.2.2.3. By Therapy
  • 6.3.3. Mexico Hemoglobinopathies Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Diagnosis
      • 6.3.3.2.3. By Therapy

7. Europe Hemoglobinopathies Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Diagnosis
  • 7.2.3. By Therapy
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Hemoglobinopathies Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Diagnosis
      • 7.3.1.2.3. By Therapy
  • 7.3.2. France Hemoglobinopathies Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Diagnosis
      • 7.3.2.2.3. By Therapy
  • 7.3.3. United Kingdom Hemoglobinopathies Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Diagnosis
      • 7.3.3.2.3. By Therapy
  • 7.3.4. Italy Hemoglobinopathies Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Diagnosis
      • 7.3.4.2.3. By Therapy
  • 7.3.5. Spain Hemoglobinopathies Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Diagnosis
      • 7.3.5.2.3. By Therapy

8. Asia Pacific Hemoglobinopathies Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Diagnosis
  • 8.2.3. By Therapy
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Hemoglobinopathies Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Diagnosis
      • 8.3.1.2.3. By Therapy
  • 8.3.2. India Hemoglobinopathies Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Diagnosis
      • 8.3.2.2.3. By Therapy
  • 8.3.3. Japan Hemoglobinopathies Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Diagnosis
      • 8.3.3.2.3. By Therapy
  • 8.3.4. South Korea Hemoglobinopathies Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Diagnosis
      • 8.3.4.2.3. By Therapy
  • 8.3.5. Australia Hemoglobinopathies Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Diagnosis
      • 8.3.5.2.3. By Therapy

9. Middle East & Africa Hemoglobinopathies Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Diagnosis
  • 9.2.3. By Therapy
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Hemoglobinopathies Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Diagnosis
      • 9.3.1.2.3. By Therapy
  • 9.3.2. UAE Hemoglobinopathies Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Diagnosis
      • 9.3.2.2.3. By Therapy
  • 9.3.3. South Africa Hemoglobinopathies Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Diagnosis
      • 9.3.3.2.3. By Therapy

10. South America Hemoglobinopathies Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Diagnosis
  • 10.2.3. By Therapy
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Hemoglobinopathies Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Diagnosis
      • 10.3.1.2.3. By Therapy
  • 10.3.2. Colombia Hemoglobinopathies Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Diagnosis
      • 10.3.2.2.3. By Therapy
  • 10.3.3. Argentina Hemoglobinopathies Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Diagnosis
      • 10.3.3.2.3. By Therapy

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Hemoglobinopathies Market : SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Sangamo Therapeutics, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Pfizer, Inc. (Global Blood Therapeutics, Inc.)
• 15.3. bluebird bio, Inc.
• 15.4. Emmaus Medical, Inc.
• 15.5. Novartis AG
• 15.6. Prolong Pharmaceuticals, LLC
• 15.7. Sanofi S.A. (Bioverativ Inc.)
• 15.8. Gamida Cell Ltd.
• 15.9. Celgene Corporation
• 15.10. Abbott Laboratories, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer